Objective: To investigate the value of delta-radiomics after the first cycle of neoadjuvant chemotherapy (NAC) using dynamic contrast-enhanced (DCE) MRI for early prediction of pathological complete response (pCR) in patients with breast cancer. Methods: From September 2018 to May 2021, a total of 140 consecutive patients (training, n = 98: validation, n = 42), newly diagnosed with breast cancer who received NAC before surgery, were prospectively enrolled. All patients underwent DCE-MRI at pre-NAC (pre-) and after the first cycle (1st-) of NAC. Radiomic features were extracted from the postcontrast early, peak, and delay phases. Delta-radiomics features were computed in each contrast phases. Least absolute shrinkage and selection operator (LASSO) and a logistic regression model were used to select features and build models. The model performance was assessed by receiver operating characteristic (ROC) analysis and compared by DeLong test. Results: The delta-radiomics model based on the early phases of DCE-MRI showed a highest AUC (0.917/0.842 for training/validation cohort) compared with that using the peak and delay phases images. The delta-radiomics model outperformed the pre-radiomics model (AUC = 0.759/0.617, p = 0.011/0.047 for training/validation cohort) in early phase. Based on the optimal model, longitudinal fusion radiomic models achieved an AUC of 0.871/0.869 in training/validation cohort. Clinical-radiomics model generated good calibration and discrimination capacity with AUC 0.934 (95%CI: 0.882, 0.986)/0.864 (95%CI: 0.746, 0.982) for training and validation cohort. Delta-radiomics based on early contrast phases of DCE-MRI combined clinicopathology information could predict pCR after one cycle of NAC in patients with breast cancer.
Breast cancer diagnosis using magnetic resonance imaging remains limited by high false-positive rates and substantial inter-reader variability, especially for lesions classified as Breast Imaging Reporting and Data System (BI-RADS) category 4, often leading to unnecessary biopsies. Here we show that the BI-RADS 4 Lesions Analysis System (BL4AS), an artificial intelligence system powered by foundation models and leveraging the rich spatiotemporal information of dynamic contrast-enhanced MRI, addresses these diagnostic challenges. Developed on a multicenter dataset of 2,803 lesions from 2,686 female patients, BL4AS demonstrates robust performance with areas under the curve of 0.892-0.930 and significantly outperforms radiologists in specificity (0.889 versus 0.491). BL4AS-assisted interpretation significantly improves diagnostic accuracy for both senior and junior radiologists, reducing inter-reader variability by 24.5% and decreasing false-positive rates by 27.3%. BL4AS further stratifies lesions into subcategories (4 A, 4B and 4 C) for refined risk assessment, offering a practical tool for precision breast cancer management.
27 November 2025 in Expert Systems with Applications
In this study, we compared first-order features of six DWI models in predicting the HER-2 expression in breast invasive ductal carcinoma, including conventional mono-exponential model derived parameter ADC, IVIM derived parameters (D, Dstar, f), DKI derived parameters (D, K), SEM derived parameters (DDC, α), FROC derived parameters (D, β, mu), CTRW derived parameters (D, α, β), and a comprehensive diagnostic logistic regression model was established to improve the diagnostic performance. We found that CTRM and IVIM derived first-order features demonstrated the powerful performance, and their combination reached the highest performance. The finding has a great value in breast cancer treatment.
In this study, we built a support vector machine (SVM) model based on quantitative parameters of continuous-time random-walk (CTRW) diffusion model in predicting the human epidermal growth factor receptor-2 (HER-2) expression in breast invasive ductal carcinoma. An AUC of 0.753 was achieved, which may have a great potential in future clinical practice.